Evidence brief
Follistatin: Gene-therapy research context and limits of extrapolation
This brief separates disease-specific research from broad claims about muscle, performance, or personal use. It does not provide a treatment or product recommendation.
Evidence maturity: limited, disease-specific human research; healthy-population claims are not established.
Human evidence
The cited early clinical work concerns a specific gene-therapy research context and does not establish the safety or efficacy of a peptide product or an intervention for healthy people.
Preclinical context
Follistatin and myostatin-pathway research frames biological questions about muscle regulation. Mechanistic relevance is not a personal-use conclusion.
What remains unknown
Long-term safety, standardized interventions, healthy-population outcome evidence, and a general clinical indication remain unestablished by the cited sources.
Human-evidence table
A structured reading aid, not a treatment or product decision tool.
| Evidence maturity | Human-study context | Interpretation limit |
|---|---|---|
| limited, disease-specific human research; healthy-population claims are not established. | The cited early clinical work concerns a specific gene-therapy research context and does not establish the safety or efficacy of a peptide product or an intervention for healthy people. | Long-term safety, standardized interventions, healthy-population outcome evidence, and a general clinical indication remain unestablished by the cited sources. |
Canadian regulatory context
Health Canada’s advisory on unauthorized injectable peptide drugs provides general safety context. This page does not assess a product or endorse a gene-therapy or peptide intervention.
Evidence timeline
- 1
Pathway research: follistatin and myostatin biology studied
- 2
Early clinical work: disease-specific gene-therapy context
- 3
Current: healthy-population and long-term intervention questions remain
Sources and maintenance
Sources are linked directly so readers can review the original material and its limitations.
- Follistatin gene-therapy study
Primary disease-specific clinical research context.
- Follistatin review
Review of the research landscape and limitations.
- Health Canada public advisory
Official Canadian information on unauthorized injectable peptide drugs.